


**In the Claims:**

Cancel the preamble and Claims 1-31, and insert therefor


-- WE CLAIM:

*Sub B11*  
32. A method for preventing, reducing, or eliminating side effects or neutralizing the effect of a cancerostatic or immunosuppressive agent administered prophylactically or therapeutically to a patient, comprising administering to the patient a compound having vitamin PP activity or a prodrug thereof.


*H2*  
33. The method of claim 32 where the compound having vitamin PP activity or a prodrug thereof is selected from the group consisting of compounds of formulae II, IIa, IIb, III, IIIa, IIIb, IIIc, IV, IVa, IVb, V, Va, and Vb:




(II)




(IIa)




(IIb)




(III)




(IIIa)




(IIIb)




(IIIc)




(IV)




(IVa)




(IVb)



(V)



(Va)



(Vb)

where:

a is an integer of 1 through 6;

b is an integer of 1 through 2;

X<sup>-</sup> is selected from the group consisting of fluoride, chloride, bromide, iodide, hydrogensulfate, mesylate, trifluoromethanesulfonate, tosylate, tetrafluoroborate, dihydrogenphosphate, and acetate;

R<sup>21</sup> is selected from the group consisting of hydrogen, halogen, cyano, alkyl, trifluoromethyl, hydroxyalkyl, hydroxy, alkoxy, alkanoyloxy, alkylthio, aminoalkyl, amino, alkylamino, dialkylamino, formyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, and carboxy;

R<sup>22</sup> is selected from the group consisting of hydrogen, halogen, alkyl, trifluoromethyl, hydroxyalkyl, hydroxy, alkoxy, alkanoyloxy, aminoalkyl, amino, alkoxycarbonyl, aminocarbonyl, and carboxy;

*See C213*  
 $A^{(i)}$  and  $D^{(i)}$  are independently a saturated or unsaturated optionally substituted aliphatic hydrocarbyl residue, optionally interrupted by a heteroatom or a functional group;

E is a bond or is a heterocyclic residue having one or two ring nitrogen atoms or one ring nitrogen atom and one ring oxygen atom, linked to  $D^{(i)}$  and G through a ring nitrogen atom and a ring carbon atom or through two ring nitrogen atoms; and


*B2*  
 G is selected from the group consisting of hydrogen, an aliphatic or araliphatic residue, an unsaturated or aromatic monocyclic or polycyclic carbocyclic residue, a saturated, unsaturated, or aromatic monocyclic or polycyclic heterocyclic residue, bonded directly or through a functional group derived from a carbon, nitrogen, oxygen, sulfur, or phosphorus atom,

and the stereoisomers or racemic or non-racemic mixtures of stereoisomers thereof,


and the tautomers thereof when G is a heterocyclic aromatic ring or an aromatic ring substituted by a hydroxy, mercapto, or amino group,

and the pharmacologically acceptable acid addition salts thereof;


(b) at least one compound selected from the group consisting of compounds of formulae II, IIa, IIb, III, IIIa, IIIb, IIIc, IV, IVa, IVb, V, Va, and Vb:




(II)




(IIa)




(IIb)




(III)




(IIIa)




(IIIb)




(IIIc)




(IV)




(IVa)




(IVb)



(V)



(Va)



(Vb)

where:

a is an integer of 1 through 6;

b is an integer of 1 through 2;

X<sup>-</sup> is selected from the group consisting of fluoride, chloride, bromide, iodide, hydrogensulfate, mesylate, trifluoromethanesulfonate, tosylate, tetrafluoroborate, dihydrogenphosphate, and acetate;

R<sup>21</sup> is selected from the group consisting of hydrogen, halogen, cyano, alkyl, trifluoromethyl, hydroxyalkyl, hydroxy, alkoxy, alkanoyloxy, alkylthio, aminoalkyl, amino, alkylamino,

di-alkylamino, formyl, alkoxy-carbonyl, amino-carbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, and carboxy;

*See C2 C13*  
 $R^{22}$  is selected from the group consisting of hydrogen, halogen, alkyl, trifluoromethyl, hydroxyalkyl, hydroxy, alkoxy, alkanoyloxy, aminoalkyl, amino, alkoxy-carbonyl, amino-carbonyl, and carboxy;

$R^{23}$  is selected from the group consisting of hydrogen, alkyl, and hydroxyalkyl;

$R^{24}$  is selected from the group consisting of alkyl, alkenyl, hydroxyalkyl, alkoxyalkyl, and aralkyl;

*B2*  
 $R^{25}$  is such that the alcohol  $R^{25}(OH)_a$  is selected from monovalent linear and branched  $C_{1-10}$  alkanols and  $\omega$ -dialkylaminoalkanols, benzyl alcohol, divalent linear and branched  $C_{2-10}$  diols, mono- or divalent  $C_{5-7}$  cycloalkanols,  $C_{5-7}$  cycloalkanediols,  $C_{5-7}$  cycloalkanemethanols, saturated  $C_{5-7}$  heterocyclomethanols, tri-, tetra-, penta-, and hexavalent linear, branched, and cyclic alcohols with 3 to 10 carbon atoms, glycerin, 2,2-bis(hydroxymethyl)-1-octanol, erythritol, pentaerythritol, arabitol, xylitol, sorbitol, mannitol, isosorbitol, tetra(hydroxymethyl)cyclohexanol, and inositol;

$R^{26}$  is selected from the group consisting of hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, dialkylaminoalkyl, and carboxymethyl;

when  $b$  is 1,  $R^{27}$  is selected from the group consisting of hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, dialkylaminoalkyl, and carboxymethyl;

when  $b$  is 2,  $R^{27}$  is alkylene in which a methylene group is optionally replaced by O, NH, or N-alkyl; and their thioxo analogs, and the acid addition salts or anionic salts thereof; and  
(c) at least one physiologically acceptable carrier.

Please add Claims 45 - 49 as follows:

45. The composition of claim 41 where:

*sub B3 cont*  
*B3*  
 $R^{21}$  is selected from the group consisting of hydrogen, halogen, cyano,  $C_{1-6}$  alkyl, trifluoromethyl,  $C_{1-6}$  hydroxyalkyl, hydroxy,  $C_{1-6}$  alkoxy,  $C_{2-7}$  alkanoyloxy,  $C_{1-6}$  alkylthio,  $C_{1-6}$  aminoalkyl, amino,  $C_{1-6}$  alkylamino, di( $C_{1-6}$  alkyl)amino, formyl, alkoxycarbonyl, aminocarbonyl, ( $C_{1-6}$  alkyl)aminocarbonyl, di( $C_{1-6}$  alkyl)aminocarbonyl, and carboxy;

$R^{22}$  is selected from the group consisting of hydrogen, halogen,  $C_{1-6}$  alkyl, trifluoromethyl,  $C_{1-6}$  hydroxyalkyl, hydroxy, alkoxy,  $C_{2-7}$  alkanoyloxy,  $C_{1-6}$  aminoalkyl, amino, ( $C_{1-6}$  alkoxy)-carbonyl, aminocarbonyl, and carboxy;

$R^{23}$  is selected from the group consisting of hydrogen,  $C_{1-6}$  alkyl, and  $C_{1-6}$  hydroxyalkyl;

$R^{24}$  is selected from the group consisting of  $C_{1-6}$  alkyl,  $C_{3-6}$  alkenyl,  $C_{2-6}$  hydroxyalkyl,  $C_{2-6}$  alkoxyalkyl, and benzyl;

$R^{26}$  is selected from the group consisting of hydrogen,  $C_{1-6}$  alkyl,  $C_{1-6}$  hydroxyalkyl,  $C_{3-6}$  alkoxyalkyl,  $C_{1-6}$  aminoalkyl,  $C_{4-12}$  dialkylaminoalkyl, and carboxymethyl;

when b is 1,  $R^{27}$  is selected from the group consisting of hydrogen,  $C_{1-6}$  alkyl,  $C_{1-6}$  hydroxyalkyl,  $C_{3-6}$  alkoxyalkyl,  $C_{1-6}$  aminoalkyl,  $C_{4-12}$  dialkylaminoalkyl, and carboxymethyl;

when b is 2,  $R^{27}$  is  $C_{2-10}$  alkylene in which a methylene group is optionally replaced by O, NH, or N-alkyl.

46. The composition of claim 41 where the compound having vitamin PP activity or a prodrug thereof is selected from the group consisting of nicotinic acid, nicotinamide, and their pharmaceutically acceptable ester and amide derivatives, anionic, quaternary, and addition salts, N-oxides, and analogous thioxo derivatives, their isomers, and prodrugs thereof.

Sub 91) 47. The composition of claim 46 where the compound having vitamin PP activity or a prodrug thereof is selected from the group consisting of nicotinic acid, nicotinamide, and mixtures thereof.

Sub P4) 48. The composition of claim 46 where the compound having vitamin PP activity or a prodrug thereof is tryptophan.

B3 49. The composition of claim 41 where the cancerostatic or immunosuppressive agent is selected from the group consisting of N-[2-(1-benzylpiperidin-4-yl)ethyl]-3-(pyridin-3-yl)propionamide;

N-{2-[1-(2-phenylethyl)piperidin-4-yl]ethyl}-3-(pyridin-3-yl)-propionamide;

N-{2-[1-(4-phenylbutyl)piperidin-4-yl]ethyl}-3-(pyridin-3-yl)-propionamide;

N-{2-[1-(4-hydroxy-4-phenylbutyl)piperidin-4-yl]ethyl}-3-(pyridin-3-yl)propionamide;

N-[2-(1-diphenylmethylpiperidin-4-yl)ethyl]-3-(pyridin-3-yl)-propionamide,

N-[3-(1-diphenylmethylpiperidin-4-yl)propyl]-3-(pyridin-3-yl)-propionamide;

N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)-propionamide;

N-[4-(1-benzylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)acrylamide;

N-{4-[1-(2-phenylethyl)piperidin-4-yl]butyl}-3-(pyridin-3-yl)-acrylamide;

N-{4-[1-(4-biphenylmethyl)piperidin-4-yl]butyl}-3-(pyridin-3-yl)acrylamide;

N-{4-[1-(1-naphthylmethyl)piperidin-4-yl]butyl}-3-(pyridin-3-yl)-acrylamide;

N-{4-[1-(9-anthrylmethyl)piperidin-4-yl]butyl}-3-(pyridin-3-yl)-acrylamide;

*Sub  
B3  
cont*

N-{4-[1-(cyclohexylphenylmethyl)piperidin-4-yl]butyl}-  
3-(pyridin-3-yl)acrylamide;  
N-{4-[1-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)piperidin-  
4-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-[2-(1-diphenylmethylnpiperidin-4-yl)ethyl]-3-(pyridin-3-yl)-  
acrylamide;  
N-[3-(1-diphenylmethylnpiperidin-4-yl)propyl]-3-(pyridin-3-yl)-  
acrylamide;  
N-[5-(1-diphenylmethylnpiperidin-4-yl)pentyl]-3-(pyridin-3-yl)-  
acrylamide;  
N-[6-(1-diphenylmethylnpiperidin-4-yl)hexyl]-3-(pyridin-3-yl)-  
acrylamide;  
*B3* N-[4-(1-diphenylmethylnpiperidin-4-yl)butyl]-5-(pyridin-3-yl)-  
2,4-pentadienic acid amide;  
N-(4-{1-[bis(4-fluorophenyl)methyl]piperidin-4-yl}butyl)-  
3-(pyridin-3-yl)acrylamide;  
N-(4-{1-[bis(2-chlorophenyl)methyl]piperidin-4-yl}butyl)-  
3-(pyridin-3-yl)acrylamide;  
N-[4-(1-diphenylmethylnpiperidin-4-yl)butyl]-3-(2-fluoro-  
pyridin-3-yl)acrylamide;  
N-[4-(1-diphenylmethylnpiperidin-4-yl)butyl]-3-(6-fluoro-  
pyridin-3-yl)acrylamide;  
N-[4-(1-diphenylmethylnpiperidin-4-yl)butyl]-3-(pyridin-3-yl)-  
acrylamide;  
N-[4-(1-diphenylmethylnpiperidin-4-yl)butyl]-3-(pyridin-3-yl)-  
acrylamide dihydrochloride;  
N-[4-(1-diphenylmethylnpiperidin-4-yl)butyl]-3-(pyridin-3-yl)-  
acrylamide methanesulfonate;  
N-[4-(1-acetylnpiperidin-4-yl)butyl]-3-(pyridin-3-yl)propionamide;  
N-[4-(1-benzoylnpiperidin-4-yl)butyl]-3-(pyridin-3-yl)-  
propionamide;



*Sub  
D  
cont*

N-[4-(1-diphenylacetylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)-  
propionamide;

N-{4-[1-(9-oxo-9H-fluoren-4-carbonyl)piperidin-4-yl]butyl}-  
3-(pyridin-3-yl)propionamide;

N-[4-(1-methylsulfonylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)-  
propionamide;

N-{4-[1-(2-naphthylsulfonyl)piperidin-4-yl]butyl}-  
3-(pyridin-3-yl)propionamide;

N-[4-(1-benzylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)propionamide;

N-(4-{1-[bis(2-chlorophenyl)methyl]piperidin-4-yl}butyl)-  
3-(pyridin-3-yl)propionamide;

*B3*

N-{4-[1-(phenylpyridin-3-ylmethyl)piperidin-4-yl]butyl}-  
3-(pyridin-3-yl)propionamide;

N-{4-[1-(9H-fluoren-9-yl)piperidin-4-yl]butyl}-3-(pyridin-3-yl)-  
propionamide;

N-{4-[1-(6,11-dihydrodibenzo[b,e]oxepin-11-yl)piperidin-4-yl]-  
butyl}-3-(pyridin-3-yl)propionamide;

N-{4-[1-(1-naphthylaminocarbonyl)piperidin-4-yl]butyl}-  
3-(pyridin-3-yl)propionamide;

N-[4-(1-diphenylaminocarbonylpiperidin-4-yl)butyl]-3-  
(pyridin-3-yl)propionamide;

N-{4-[1-(10,11-dihydrodibenzo[b,f]azepin-5-yl-carbonyl)piperidin-  
4-yl]butyl}-3-(pyridin-3-yl)propionamide;

N-[4-(1-diphenylphosphinoylpiperidin-4-yl)butyl]-  
3-(pyridin-3-yl)propionamide;

N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-3-(2-fluoropyridin-3-  
yl)propionamide;

N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-3-(5-fluoropyridin-3-  
yl)propionamide;

N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-2-fluoro-  
3-(pyridin-3-yl)propionamide;

N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-2,2-difluoro-  
3-(pyridin-3-yl)propionamide;

Sub  
B3  
cont

N-[5-(1-diphenylmethylpiperidin-4-yl)pentyl]-3-(pyridin-3-yl)-propionamide;

N-[6-(1-diphenylmethylpiperidin-4-yl)hexyl]-3-(pyridin-3-yl)-propionamide;

N-[2-(1-diphenylmethylpiperidin-4-yl)ethyl]-5-(pyridin-3-yl)-pentanoic acid amide;

N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-5-(pyridin-3-yl)-pentanoic acid amide;

N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-N-hydroxy-3-(pyridin-3-yl)propionamide;

N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-2-hydroxy-3-(pyridin-3-yl)propionamide;

B3 N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-3-hydroxy-3-(pyridin-3-yl)propionamide;

N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)-propionamide;

N-[4-(1-methylsulfonylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)-acrylamide;

N-[4-[1-(2-naphthylsulfonyl)piperidin-4-yl]butyl]-3-(pyridin-3-yl)acrylamide;

N-[4-[1-(2-naphthylsulfonyl)piperidin-4-yl]butyl]-5-(pyridin-3-yl)-2,4-pentadienic acid amide;

N-[4-[1-(1-naphthylaminocarbonyl)piperidin-4-yl]butyl]-3-(pyridin-3-yl)acrylamide;

N-[4-(1-diphenylaminocarbonylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)acrylamide;

N-[4-(1-diphenylaminocarbonylpiperidin-4-yl)butyl]-5-(pyridin-3-yl)-2,4-pentadienic acid amide;

N-[4-[1-(10,11-dihydrodibenzo[b,f]azepin-5-yl-carbonyl)piperidin-4-yl]butyl]-3-(pyridin-3-yl)-acrylamide;

N-[4-(1-diphenylphosphinoylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)acrylamide;

N-[4-(1-acetylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)acrylamide;

*for  
B3  
cont*

N-[4-(1-diphenylacetyl)piperidin-4-yl]-butyl]-3-(pyridin-3-yl)-acrylamide;

N-{4-[1-(3,3-diphenylpropionyl)piperidin-4-yl]-butyl}-3-(pyridin-3-yl)acrylamide;

N-[4-(1-benzoylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)acrylamide;

N-[4-(1-benzoylpiperidin-4-yl)butyl]-5-(pyridin-3-yl)-2,4-pentadienic acid amide;

N-{4-[1-(9-oxo-9H-fluoren-4-ylcarbonyl)piperidin-4-yl]butyl}-3-(pyridin-3-yl)acrylamide;

N-{4-[1-(phenylpyridin-3-ylmethyl)piperidin-4-yl]-butyl}-3-(pyridin-3-yl)acrylamide;

*B3* N-{4-[1-(phenylpyridin-4-ylmethyl)piperidin-4-yl]-butyl}-3-(pyridin-3-yl)acrylamide;

N-{4-[1-(6,11-dihydrodibenzo[b,e]oxepin-11-yl)piperidin-4-yl]-butyl}-3-(pyridin-3-yl)acrylamide;

N-{4-[1-(6,11-dihydrodibenzo[b,e]thiepin-11-yl)piperidin-4-yl]-butyl}-3-(pyridin-3-yl)acrylamide;

N-[7-(1-diphenylmethylpiperidin-4-yl)heptyl]-3-(pyridin-3-yl)-acrylamide;

N-[8-(1-diphenylmethylpiperidin-4-yl)octyl]-3-(pyridin-3-yl)-acrylamide;

N-[3-(1-diphenylmethylpiperidin-4-yloxy)propyl]-3-(pyridin-3-yl)-acrylamide;

N-[3-(1-benzylpiperidin-4-yloxy)propyl]-3-(pyridin-3-yl)-acrylamide;

N-[2-(1-diphenylmethylpiperidin-4-yl)ethyl]-5-(pyridin-3-yl)-2,4-pentadienic acid amide;

N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-5-(pyridin-3-yl)-2,4-pentadienic acid amide;

N-[5-(1-diphenylmethylpiperidin-4-yl)pentyl]-5-(pyridin-3-yl)-2,4-pentadienic acid amide;

N-[6-(1-diphenylmethylpiperidin-4-yl)hexyl]-5-(pyridin-3-yl)-2,4-pentadienic acid amide;

*Sub  
P  
cont*

N-[4-(4-diphenylmethylpiperazin-1-yl)-3-hydroxybutyl]-  
3-(pyridin-3-yl)acrylamide;  
N-[3-(4-diphenylmethylpiperazin-1-yl)propoxy]-3-(pyridin-3-yl)-  
acrylamide;  
N-[4-(4-diphenylmethylpiperazin-1-yl)-4-oxobutyl]-  
3-(pyridin-3-yl)acrylamide;  
N-[3-(4-diphenylmethylpiperazin-1-sulfonyl)propyl]-  
3-(pyridin-3-yl)acrylamide;  
N-{2-[2-(4-diphenylmethylpiperazin-1-yl)ethoxy]ethyl}-  
3-(pyridin-3-yl)acrylamide;  
N-(4-{4-[bis(4-fluorophenyl)methyl]piperazin-1-yl}but-2-enyl)-  
3-(pyridin-3-yl)acrylamide;  
*B3* N-(4-{4-[(4-carboxyphenyl)phenylmethyl]piperazin-1-yl}butyl)-  
3-(pyridin-3-yl)acrylamide;  
N-(4-{4-[(4-aminophenyl)phenylmethyl]piperazin-1-yl}butyl)-  
3-(pyridin-3-yl)acrylamide;  
N-{4-[4-(9H-fluoren-9-yl)piperazin-1-yl]butyl}-  
2-(pyridin-3-yloxy)acetamide;  
N-{5-[4-(9H-fluoren-9-yl)piperazin-1-yl]pentyl}-3-(pyridin-3-yl)-  
acrylamide;  
N-{6-[4-(9H-fluoren-9-yl)piperazin-1-yl]hexyl}-3-(pyridin-3-yl)-  
acrylamide;  
3-(pyridin-3-yl)-N-{4-[4-(1,2,3,4-tetrahydronaphthalen-1-yl)-  
piperazin-1-yl]butyl}acrylamide;  
3-(pyridin-3-yl)-N-{4-[4-(5,6,7,8-tetrahydronaphthalen-1-yl)-  
piperazin-1-yl]butyl}acrylamide;  
N-{4-[4-(naphthalen-1-yl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)-  
acrylamide;  
N-[4-(4-biphenyl-2-ylpiperazin-1-yl)butyl]-3-(pyridin-3-yl)-  
propionamide;  
N-[5-(4-biphenyl-2-ylpiperazin-1-yl)pentyl]-3-(pyridin-3-yl)-  
acrylamide;

*Sub  
P  
cont*

N-[6-(4-biphenyl-2-ylpiperazin-1-yl)hexyl]-3-(pyridin-3-yl)-acrylamide;

N-[4-(4-biphenyl-2-ylpiperazin-1-yl)butyl]-2-(pyridin-3-yloxy)-acetamide;

N-[4-(4-biphenyl-2-ylpiperazin-1-yl)butyl]-5-(pyridin-3-yl)-2,4-pentadienic acid amide;

N-{4-[4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-piperazin-1-yl]butyl}-3-(pyridin-3-yl)propionamide;

N-{5-[4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-piperazin-1-yl]pentyl}-3-(pyridin-3-yl)acrylamide;

*B3* N-{6-[4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-piperazin-1-yl]hexyl}-3-(pyridin-3-yl)acrylamide;

N-{4-[4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-piperazin-1-yl]butyl}-5-(pyridin-3-yl)-2,4-pentadienic amide;

N-{4-[4-(6,11-dihydrodibenzo[b,e]oxepin-11-yl)piperazin-1-yl]-butyl}-3-(pyridin-3-yl)propionamide;

N-{2-[4-(6,11-dihydrodibenzo[b,e]thiepin-11-yl)piperazin-1-yl]-ethyl}-3-(pyridin-3-yl)acrylamide;

N-[4-(4-diphenylacetyl)piperazin-1-yl]butyl]-3-(pyridin-3-yl)-acrylamide;

N-[4-(4-benzoylpiperazin-1-yl)butyl]-3-(pyridin-3-yl)acrylamide;

N-{4-[4-(2-aminobenzoyl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)-acrylamide;

N-{4-[4-(4-carboxybenzoyl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)-acrylamide;

N-{4-[4-(biphenyl-2-carbonyl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)acrylamide;

N-{4-[4-(9-oxo-9H-fluoren-4-carbonyl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)acrylamide;

N-{4-[4-(furan-2-carbonyl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)-acrylamide;

N-{4-[4-(naphthalen-1-ylaminocarbonyl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)propionamide;

*Sub 204 cont*

N-{4-[4-(diphenylaminocarbonyl)piperazin-1-yl]butyl}-  
3-(pyridin-3-yl)acrylamide;  
N-{4-[4-(naphthalen-2-sulfonyl)piperazin-1-yl]butyl}-  
3-(pyridin-3-yl)acrylamide;  
N-[4-(4-diphenylphosphinonylpiperazin-1-yl)butyl]-  
3-(pyridin-3-yl)acrylamide;  
N-[4-(4-biphenyl-2-yl)piperazin-1-yl]butyl]-3-(pyridin-3-yl)-  
acrylamide;  
N-{4-[4-(9H-fluoren-9-yl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)-  
acrylamide;  
N-{4-[4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)piperazin-  
1-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
*B3* N-[4-(4-phenylpiperidin-1-yl)-butyl]-3-(pyridin-3-yl)acrylamide;  
N-{4-[4-(1H-indol-3-yl)piperidin-1-yl]butyl}-3-(pyridin-3-yl)-  
acrylamide;  
N-{4-[4-(2-oxo-2,3-dihydrobenzimidazol-1-yl)piperidin-1-yl]-  
butyl}-3-(pyridin-3-yl)acrylamide;  
N-[4-(4-benzotriazol-1-yl)piperidin-1-yl]butyl]-3-(pyridin-3-yl)-  
acrylamide;  
N-{4-[4-(hydroxydiphenylmethyl)piperidin-1-yl]butyl}-  
2-(pyridin-3-yloxy)acetamide;  
N-[4-(4,4-diphenylpiperidin-1-yl)butyl]-3-(pyridin-3-yl)-  
acrylamide;  
N-{4-[4-(6,11-dihydrodibenzo[b,e]thiepin-11-yliden)-  
piperidin-1-yl]butyl}-3-(pyridin-3-yl)propionamide  
dihydrochloride semi-isopropanol;  
N-{4-[4-(6,11-dihydrodibenzo[b,e]thiepin-11-yliden)-  
piperidin-1-yl]butyl}-5-(pyridin-3-yl)pentanamide;  
N-{4-[4-(4,9-dihydrothieno[2,3-b]benzo[e]thiepin-4-yliden)-  
piperidin-1-yl]butyl}-3-(pyridin-3-yl)propionamide;  
N-{4-[4-(4,9-dihydrothieno[2,3-b]benzo[e]thiepin-4-yliden)-  
piperidin-1-yl]butyl}-3-(pyridin-3-yl)acrylamide;

*not  
cont*

N-[4-(4-diphenylphosphinoyloxypiperidin-1-yl)butyl]-  
3-(pyridin-3-yl)acrylamide;  
N-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)butyl]-3-(pyridin-3-yl)-  
acrylamide;  
N-[4-(2,5-dioxo-3,4-diphenyl-2,5-dihydropyrrol-1-yl)butyl]-  
3-(pyridin-3-yl)acrylamide;  
N-[4-(2,6-dioxo-4-phenylpiperidin-1-yl)butyl]-3-(pyridin-3-yl)-  
acrylamide;  
N-[4-(1,3-dioxo-4,5,6,7-tetraphenyl-1,3-dihydroisoindol-2-yl)-  
butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(3-benzyl-2,4,5-trioxoimidazolidin-1-yl)butyl]-  
3-(pyridin-3-yl)acrylamide;  
*B3* N-[4-(1,3,10-trioxo-1,4,5,6,10,10a-hexahydroacenaphtho[1,8a-c]-  
pyrrol-2-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(2,5-dioxo-4,4-diphenylimidazolidin-1-yl)butyl]-  
3-(pyridin-3-yl)acrylamide;  
N-[4-(2,5-dioxo-3-phenyl-2,5-dihydropyrrol-1-yl)butyl]-  
3-(pyridin-3-yl)acrylamide;  
N-[3-(2,5-dioxo-3,4-diphenyl-2,5-dihydropyrrol-1-yl)propyl]-  
3-(pyridin-3-yl)acrylamide;  
N-[4-(3-pyridin-3-ylacryloylamino)butyl]-2,3:5,6-dibenzo-  
bicyclo[2.2.2]octan-7,8-dicarboximide;  
N-[4-(5-benzyliden-2,4-dioxothiazolidin-3-yl)butyl]-  
3-(pyridin-3-yl)acrylamide;  
N-[4-(4-benzyl-2,6-dioxopiperazin-1-yl)butyl]-3-(pyridin-3-yl)-  
acrylamide;  
N-[6-(2,5-dioxo-3,4-diphenyl-2,5-dihydropyrrol-1-yl)hexyl]-  
3-(pyridin-3-yl)acrylamide;  
N-[4-(2,5-dioxo-3,4-diphenyl-2,5-dihydropyrrol-1-yl)butyl]-  
3-(pyridin-3-yl)propionamide;  
N-[4-(1,3-dioxo-1,3-dihydroisoindol-2-yl)butyl]-3-(pyridin-3-yl)-  
acrylamide;

*Sub  
B3  
cont*

N-[4-(1,3-dioxo-1H,3H-benzo[de]isoquinolin-2-yl)butyl]-  
3-(1-oxopyridin-3-yl)acrylamide;  
N-[6-(1,3-dioxo-1H,3H-benzo[de]isoquinolin-2-yl)hexyl]-  
3-(pyridin-3-yl)acrylamide;  
N-[2-(1,3-dioxo-1H,3H-benzo[de]isoquinolin-2-yl)ethyl]-  
3-(pyridin-3-yl)acrylamide;  
N-[4-(1,3-dioxo-1H,3H-benzo[de]isoquinolin-2-yl)butyl]-  
3-(pyridin-3-yl)acrylamide;  
N-[8,8-bis(4-fluorophenyl)octyl]-3-(pyridin-3-yl)acrylamide  
hydrochloride;  
N-[6-(3,3-diphenylureido)hexyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(1-phenyl-1,2,4,5-tetrahydrobenzo[d]azepin-3-yl)butyl]-  
*B3* 3-(pyridin-3-yl)acrylamide;  
N-(8,8-diphenyloctyl)-3-(pyridin-3-yl)acrylamide;  
N-(8-hydroxy-8,8-diphenyloctyl)-3-(pyridin-3-yl)acrylamide;  
N-[4-(3,3-diphenylureido)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(1H,3H-benzo[de]isoquinolin-2-yl)butyl]-3-(pyridin-3-yl)-  
acrylamide;  
N-[6-(10,11-dihydrodibenzo[b,f]azepin-5-ylcarbonylamino)hexyl]-  
3-(pyridin-3-yl)acrylamide;  
3-(pyridin-3-yl)-N-[6-tosylaminohexyl]acrylamide;  
N-[4-(1,1-dioxo-1-thia-2-azaacenaphthylen-2-yl)butyl]-3-(pyridin-  
3-yl)acrylamide;  
N-(6-hydroxy-6,6-diphenylhexyl)-3-(pyridin-3-yl)acrylamide;  
N-(6,6-diphenylhex-5-enyl)-3-(pyridin-3-yl)acrylamide;  
N-[4-(4,5-diphenylimidazol-1-yl)butyl]-3-(pyridin-3-yl)-  
acrylamide;  
N-[4-(trans-2-phenylcyclopropylcarbonylamino)butyl]-  
3-(pyridin-3-yl)acrylamide;  
N-(5-hydroxy-5,5-diphenylpentyl)-3-(pyridin-3-yl)acrylamide;  
N-(7-phenylheptyl)-3-(pyridin-3-yl)acrylamide;  
N-(4-diphenylacetylaminobutyl)-3-(pyridin-3-yl)acrylamide;  
N-[4-(benzhydrylamino)butyl]-3-(pyridin-3-yl)acrylamide; and